MoonLake reveals notable advancements using Nanobody® sonelokimab over a six-month period for treating active psoriatic arthritis (PsA), along with other crucial updates during its research and development event.

Prazosin, a minuscule molecule drug, exhibits antagonistic properties towards α1A-AR, α1B-AR, and α1D-AR receptors.

Latest findings from the second phase of testing indicate that amlitelimab may be a top-performing contender for sustained treatment effectiveness in managing eczema.

Domain Therapeutics secured nearly €10M from the French National Research Agency via the "Hospital-University Health Research SPRINT Alliance" in January, to advance precision medicine and bring their lead drug DT-7012 to clinical trials.

RemeGen Showcases Study of Unique Disitamab Vedotin (RC48) in Treating Cervical Cancer through Verbal Presentation at 2024 ESGO Event.

Digoxin, a small molecule, is known for inhibiting Na/K-ATPase, increasing intracellular calcium, and thus enhancing heart function.

Sensorion Reveals Achievement of Main Goal in Phase 2a Trial of SENS-401 for Preserving Remaining Hearing Function.

On March 6th, Nature Reviews Drug Discovery highlighted recent bispecific antibodies (bsAbs) progress in cancer therapy.

Celltrion USA has finalized their application for a biologic license to the U.S. Food and Drug Administration for CT-P39, their alternative biosimilar to XOLAIR (omalizumab).

Phenazopyridine, a diminutive molecule, serves primarily as an analgesic agent for urinary tract pain.

Wegovy® receives green light in the USA to diminish heart-related health hazards for those excessively heavy or with obesity coupled with confirmed heart conditions.

In investigating obesity treatment, the GLP-1 receptor, key for managing Type 2 diabetes and heart disease, is a major focus.